Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 4Terminated 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Gastrointestinal 1

Conditions

Pituitary Neoplasms 3Nelson Syndrome 2Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Carcinoma, Intraductal, Noninfiltrating 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

pasireotide 3lanreotide 1Temozolomide 1Rosiglitazone 1Pafolacianine 1Endoscopic Mucosal Resection 1Dexamethasone 1Capecitabine 1Calcium Dobesilate 1Cabergoline 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Pituitary Neoplasms × pasireotide × Clear all
NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT00929669 2017-11-28

LAR

University of Pennsylvania

Phase 2 Terminated
2 enrolled 3 charts
Endocrine

Pituitary Neoplasms

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Novartis

Phase 2 Terminated
118 enrolled 11 charts
EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡